[ad_1]
Top articles from this morning in the Proactive Investors UK press room.
Avacta Group PLC (LON: AVCT) has announced that it will go to the clinic "well before the initial plans" with a drug candidate combining its binding protein technology with chemotherapy. Microenvironmentally Activated and Tumor Activated Drug Conjugates (TMACs) are a revolutionary new form of cancer immunotherapy.
Argo Blockchain PLC (LON: ARB) has announced "significantly better" market conditions since early May and has raised expectations for its second quarter thanks to improved prices in the cryptocurrency market. The mining cryptography services group said in a trading update that its May results were "significantly ahead" of internal budgets, reflecting improved market conditions as well as the delivery of cryptographic hardware. mining earlier than planned.
WideCells (LON: WDC) announced that its new media company, Iconic Labs, had reached an agreement and started work on a consulting and marketing services contract with a UK-based financial services company. The relationship is based on long-term holdbacks, with initial revenues of more than £ 1 million in the first year.
Sareum Holdings (LON: SAR) has announced that Sierra Oncology has reported preliminary positive clinical data from its first two human phase 2 studies.
Benchmark Holdings PLC (LON: BMK) expects its annual results to be in line with market estimates, after a 23% rise in adjusted earnings (EBITDA) in the first half of the year. The aquaculture company specializing in health, nutrition and genetics has recorded an adjusted EBITDA of £ 7.5 million for the first half, for a turnover of £ 78.3 million, up from 3.4 % compared to a year ago.
Source link
